Sign In
Buy IMMX
$8.44
+0.0750 (+0.90%)
At Close: Jun 03, 2026
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
10:55am, Wednesday, 27'th May 2026
The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
05:15pm, Friday, 22'nd May 2026
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, �
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
06:30am, Thursday, 21'st May 2026
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
06:00am, Thursday, 21'st May 2026
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 yea
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
08:45am, Thursday, 09'th Apr 2026
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis,
Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) Price Target at $18.25
01:09am, Monday, 06'th Apr 2026
Shares of Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. One
– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded C
Immix Biopharma (IMMX) to Release Earnings on Monday
01:36am, Monday, 16'th Mar 2026
Immix Biopharma (NASDAQ: IMMX - Get Free Report) is projected to announce its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Immix Biopharma to post earnings of ($0.16)
Immix Biopharma to Participate in Upcoming Investor Conferences
08:45am, Tuesday, 03'rd Mar 2026
LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis,
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
08:45am, Wednesday, 28'th Jan 2026
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting –
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition
12:10am, Thursday, 11'th Dec 2025
Immix Biopharma (IMMX) is advancing NXC-201, a one-time CAR T therapy for AL amyloidosis, showing 95% complete/near-complete response rates and superior safety. IMMX's recent $100 million financing re
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
05:45pm, Tuesday, 09'th Dec 2025
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”,
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
06:20pm, Sunday, 07'th Dec 2025
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, tod
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
08:45am, Wednesday, 12'th Nov 2025
- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® -
